

November 5, 2020

The Manager (Listing)

BSE Limited

Phiroze Jeejeebhoy Towers

Dalal Street, Fort

Mumbai 400 023

Fax No.2272 5092/3030

Ref. Scrip code: 539680

Sub.: Outcome of Board Meeting held today i.e. November 5, 2020

Dear Sir,

With reference to the captioned subject and in compliance with the regulation 30 and other applicable regulation of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, this is to inform you that the Board of Directors of the Company at its meeting held today i.e. November 5, 2020 (commenced at 12:30 p.m. and concluded at 1:00 p.m. inter-alia have considered and approved the un-audited financial results of the Company for the half year ended on September 30, 2020.

A copy of the un-audited Financial Results adopted and approved by the Board of Directors for the half year ended on September 30, 2020 along with limited review report of the Auditors thereon is attached herewith.

Please take the same on your records and suitably disseminated at all concerned.

Thanking you,

Yours faithfully,


For Ganga Pharmaceuticals Limited

  
Bharat Sharma

Managing Director

DIN: 00077026

Email ID: [bharat.sharma@gangapharma.in](mailto:bharat.sharma@gangapharma.in)



**Regd. Office & Factory :** Gangatat, Dhanyantri Marg, Gopchar Pada, Virar (E), 401 305, (Mumbai) INDIA

Tel. : 84520 49222 / 99678 40111

e-mail : [gplvirar@gmail.com](mailto:gplvirar@gmail.com) / [gangapharmaltd@gmail.com](mailto:gangapharmaltd@gmail.com) • Website : [www.ayurvedganga.com](http://www.ayurvedganga.com)

CIN No. : L99999MH1989PLC053392

GST No. : 27AABCG3922H1ZS

## GANGA PHARMACEUTICALS LIMITED

CIN: L99999MH1989PLC053392

REGISTERED OFFICE ADDRESS : GANGATAT, DHANVANTARI MARG, GOPCHAR PADA, VIRAR (EAST)-401305

Tele No. +91-250-6098444 Email id: gangapharmaltd@gmail.com , Website: www.ayurvedganga.com

## Statement of Unaudited Financial Results for the Half and Year ended 30 September, 2020


Sr. No	Particulars	Rs.in Lacs				
		Figures for the half year ended on			Financial year ended on	Financial year ended on
		30-09-2020	31/03/2020	30/09/2019	31-03-2020	31-03-2019
		(Un-Audited)	(Audited)	(Un-Audited)	(Audited)	(Audited)
1	<b>INCOME FROM OPERATIONS</b>					
	(a) Revenue from operations	114.48	169.64	138.24	307.88	336.26
	(b) Other Income	6.73	9.01	7.50	16.51	14.39
	<b>Total Income</b>	<b>121.21</b>	<b>178.66</b>	<b>145.74</b>	<b>324.39</b>	<b>350.65</b>
2	<b>Expenses:</b>					
	(a) Cost of Materials consumed	47.57	52.09	64.20	116.29	124.57
	(b) Purchase of stock in trade				-	-
	(c) Change in inventories of finished, WIP and stock in trade	7.94	8.30	3.12	11.42	(1.17)
	(d) Employee Benefit Expenses	26.02	29.35	14.28	43.63	44.52
	(e) Finance Cost	9.47	12.05	12.18	24.23	25.13
	(f) Depreciation and Amortization Expense	2.68	2.82	2.60	5.42	5.29
	(g) Other Administrative Expenses	25.35	69.52	28.37	97.89	126.47
	<b>Total Expenses</b>	<b>119.03</b>	<b>174.13</b>	<b>124.75</b>	<b>298.89</b>	<b>324.80</b>
3	<b>Profit/(Loss) before Tax (1-2)</b>	<b>2.18</b>	<b>4.53</b>	<b>20.98</b>	<b>25.51</b>	<b>25.85</b>
4	<b>Tax Expenses</b>					
	(a) Current Tax	0.57	1.03	5.29	6.32	6.63
=	(b) Deferred Tax	(0.04)	0.14	0.16	0.31	0.50
5	<b>Net Profit / (Loss) for the period (3-4)</b>	<b>1.65</b>	<b>3.36</b>	<b>15.53</b>	<b>18.88</b>	<b>18.71</b>
6	<b>Other Comprehensive Income</b>			-	-	-
7	<b>Paid - Up equity share capital ( Equity Share of Rs. 10/- each)</b>	<b>406.15</b>	<b>406.15</b>	<b>406.15</b>	<b>406.15</b>	<b>406.15</b>
8	<b>Earning per equity share (Rs.)</b>					
	(1) Basic	0.04	0.42	0.04	0.46	0.46
	(2) Diluted	0.04	0.42	0.04	0.46	0.46

## Note

- The above results for the half year ended 30-09-2020 have been reviewed by the Audit Committee in their meeting held on 05th Nov 2020 and approved by the Board of Directors in their meeting held on 05th Nov 2020.
- By mid of March 2020, novel corona virus (Covid-19) had spread across the world and since then the pandemic has severely affected public health and disrupted economic activities. In response to this pandemic, Governments across the world had to impose various restrictions including lockdowns and mandatory work from home requirements. This has affected the operations of the Company and has had impact on the sales and profitability amongst others. The Company is continuously monitoring the situation and taking necessary actions in response to the developments to minimise the impact and also to safeguard the assets and employees.
- Previous period's figures have been regrouped/reclassified wherever necessary.

For and on behalf of the Board of Directors  
Ganga Pharmaceuticals Limited

Bharat Sharma  
Managing Director  
DIN : 00077026  
Place: Mumbai  
Date : 05th Nov, 2020





**GANGA PHARMACEUTICALS LTD**

CIN: L99999MH1989PLC053392

Registered Office: Gangatat, Dhanvantari Marg, Gopcharpada, Virar (East), Palghar -401305

Tele Nos.:0250-6098333/444 ; Website: www.ayurvedganga.com; Email id:gangapharmaltd@gmail.com

**Statement of Assests and Liabilities as at 30th September 2020**

Amt in Rs.

	Statement of Assets and Liabilities Particulars	As at (30-09-2020)	As at (31-03-2020)
<b>A</b>	<b>EQUITY AND LIABILITIES</b>		
	<b>(1) Shareholders Funds:</b>		
	(a) Share Capital	406,15,000	406,15,000
	(b) Reserve & Surplus	130,76,066	129,10,545
	<b>(2) Non-Current Liabilities</b>		
	(a) Long-Term Borrowings	69,24,436	59,27,500
	(b) Deferred Tax Liabilities (Net)	52,758	57,249
	(c) Other Long Term Liabilities	-	-
	(d) Long Term Provisions	-	-
	<b>(3) Current Liabilities</b>		
	(a) Short-term borrowings	120,83,483	85,91,056
	(b) Trade payables		
	i) Total outsatnding dues of micro enterprises and small enterprises	16,80,985	13,55,720
	ii) Total outsatnding dues of creditors other then micro enterprises and small enterprises	31,53,710	42,10,758
	(c) Other current liabilities	11,41,880	19,81,630
	(d) Short-term provisions	78,215	21,582
	<b>Total</b>	<b>788,06,534</b>	<b>756,71,040</b>
<b>B</b>	<b>ASSETS</b>		
	<b>(1) Non - Current assets</b>		
	(a) Fixed Assets	73,66,940	75,78,167
	(b) Non-current investments	8,92,500	8,92,500
	(c) Deferred tax assets (net)	-	-
	(d) Long term loans and advances	-	-
	(e) Other Non-current assets	234,09,051	230,21,411
	<b>(2) Current assets</b>		
	(a) Current Investment	-	-
	(b) Inventories	109,94,505	103,95,750
	(c) Trade receivables	108,20,637	107,05,650
	(d) Cash and cash equivalents	3,28,626	1,16,730
	(e) Short-term loans and advances	115,29,374	122,79,870
	(f) Other current assets	134,64,901	106,80,962
	<b>Total</b>	<b>788,06,534</b>	<b>756,71,040</b>

For and on behalf of the Board of Directors of  
Ganga Pharmaceuticals Limited

Bharat Sharma  
Managing Director  
DIN : 00077026



Place: Mumbai

Date : 05th Nov, 2020

**GANGA PHARMACEUTICALS LIMITED****Cash Flow Statement for the period Ended 30 Septmeber 2020**

	30th September Rupees	30th September Rupees	31st March 2020 Rupees	31st March 2020 Rupees
<b>A. Cash flow from operating activities:</b>				
Net profit before tax as per Profit and Loss Account.		2,17,663		25,50,763
Adjustment to reconcile profit before tax to net cash flows :				
Depreciation and amortisation expense	2,67,599		5,41,669	
Interest on advance & deposit recd	(6,72,861)		(16,46,020)	
Finance cost	9,47,352		21,81,865	
Prior period Item	-		-	
		5,42,090		10,77,514
Operating profit before working capital changes		7,59,753		36,28,277
Movements in working capital:				
(Decrease) / Increase in trade payables	(7,31,783)		84,323	
(Decrease) / Increase in other liabilities	(7,83,117)		2,19,998	
(Decrease) / Increase in Short term	34,92,427		(35,15,978)	
(Increase) / Decrease in trade receivables	(1,14,987)		15,58,576	
(Increase) / Decrease in other current assets	(27,83,939)		(55,43,159)	
(Increase) / Decrease in Short-term loans and advances	7,50,496		(86,662)	
(Increase) / Decrease in Inventories	(5,98,755)		11,42,340	
		(7,69,657)		(61,40,562)
<b>Cash generated from operations</b>		<b>(9,904)</b>		<b>(25,12,286)</b>
Taxes paid		(56,633)		(5,51,758)
<b>Net cash from operating activities</b>		<b>(66,537)</b>		<b>(30,64,044)</b>
<b>B. Cash flow from investing activities:</b>				
Purchase of fixed assets	(56,372)		(1,01,115)	
Advances given	(3,87,640)		-	
Deposit made / matured during the year	-		21,47,964	
Investment made during the year	-		-	
Interest received	6,72,861		16,46,020	
<b>Net cash used in investing activities</b>		<b>2,28,849</b>		<b>36,92,869</b>



**GANGA PHARMACEUTICALS LIMITED**  
**Cash Flow Statement (Contd.)**

	31st March 2020 Rupees	31st March 2020 Rupees	31st March 2020 Rupees	31st March 2020 Rupees
<b>C. Cash flow from financing activities:</b>				
Repayment of borrowings	9,96,936		(6,95,588)	
Proceeds from borrowings	-		-	
Finance cost	(9,47,352)		(21,81,865)	
<b>Net cash used in financing activities</b>		<b>49,584</b>		<b>(28,77,453)</b>
<b>Net increase / (Decrease) in cash and cash equivalents</b>		<b>2,11,896</b>		<b>(22,48,628)</b>
<b>Cash and cash equivalents as at the beginning of the year</b>		<b>1,16,730</b>		<b>23,65,357</b>
<b>Cash and cash equivalents as at the end of the year</b>		<b>3,28,626</b>		<b>1,16,730</b>
<b>Cash and cash equivalent comprises of :</b>				
Cash in hand		1,90,339		1,96,085
Balance with banks		1,38,287		(79,355)
<b>Total</b>		<b>3,28,626</b>		<b>1,16,730</b>

**Notes:**

- 1 The above Cash Flow Statement has been prepared under the "Indirect Method" as set out in the Notified Accounting Standard - 3 on Cash Flow Statements.
- 2 Figures in bracket indicate cash outgo.
- 3 Previous years' figures have been regrouped/rearranged to conform with current years' classifications.

As per our report of even date

**For and on behalf of the Board of Directors of  
Ganga Pharmaceuticals Limited**

**Bharat Sharma**  
**Managing Director**  
**DIN : 00077026**



**Place :- Mumbai**  
**Date :- 05th November 2020**



# **Anil Bansal & Associates**

— CHARTERED ACCOUNTANTS —

## **INDEPENDENT AUDITORS LIMITED REVIEW REPORT ON UNAUDITED FINANCIAL RESULTS OF THE COMPANY FOR THE HALF YEAR ENDED 30.09.2020 PURSUANT TO THE REGULATION 33 OF THE SEBI (LISTING OBLIGATIONS AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2015 (AS AMENDED)**


**To  
The Board of Director  
Ganga Pharmaceuticals Ltd**

We have reviewed the accompanying statement of unaudited financial results of **Ganga Pharmaceuticals Ltd** for the period ended on 30th September, 2020. This Statement is the responsibility of the Company's Management and has been approved by the Board of Director. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (RE) 2410 "Review of Interim Financial Information performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any materials misstatement.

**For: Anil Bansal & Associates  
Chartered Accountants  
Firm Registration No. 100421W**

  
**Anil Bansal  
Proprietor  
Membership Number 043918  
UDIN: 20043918AAAADL2156  
Place- Mumbai  
Date- 05th November, 2020**